Trial Profile
Phase 1b Controlled Double Blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of the Candidate Plasmodium Falciparum Malaria Protein 010 (FMP010) Administered Intramuscularly With Glaxo Smith Kline (GSK) Biologicals' Adjuvant AS01B
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 03 Jul 2023
Price :
$35
*
At a glance
- Drugs FMP010 vaccine (Primary) ; AS01B; Rabies vaccine
- Indications Falciparum malaria
- Focus Adverse reactions
- 08 Jun 2015 New trial record